Eur radiol:乳房长肿块了?容积定量动态对比增强MRI在鉴别良恶性乳腺病变的价值

2017-10-01 shaosai MedSci原创

女性乳腺是由皮肤、纤维组织、乳腺腺体和脂肪组成的,乳腺癌是发生在乳腺腺上皮组织的恶性肿瘤。乳腺癌中99%发生在女性,男性仅占1%。乳腺癌的早期发现、早期诊断,是提高疗效的关键。应结合患者的临床表现及病史、体格检查、影像学检查、组织病理学和细胞病理学检查(在有条件的医院),进行乳腺癌的诊断与鉴别诊断。本研究旨在验证容积定量动态对比增强MRI(qDCE-MRI)在鉴别良恶性乳腺病变的价值,并将结果发表

女性乳腺是由皮肤、纤维组织、乳腺腺体和脂肪组成的,乳腺癌是发生在乳腺腺上皮组织的恶性肿瘤。乳腺癌中99%发生在女性,男性仅占1%。乳腺癌的早期发现、早期诊断,是提高疗效的关键。应结合患者的临床表现及病史、体格检查、影像学检查、组织病理学和细胞病理学检查(在有条件的医院),进行乳腺癌的诊断与鉴别诊断。本研究旨在验证容积定量动态对比增强MRI(qDCE-MRI)在鉴别良恶性乳腺病变的价值,并将结果发表在Eur radiol上。

本研究共纳入了124例患者,包括136处乳腺病变。利用二舱制扩展Tofts模型和3D感兴趣区测量定量药代动力学参数(包括K trans、K ep、V e、 V p )和半定量参数(包括TTP、MaxCon、MaxSlope、AUC)。评估形态学特点(病变大小、边界、强化方式)和时间信号强度曲线(TIC)类型。利用Logistic回归曲线验证验证恶性的预测因子,进而利用ROC曲线评估诊断效能。

结果为,qDCE参数(K trans、K ep、V p、TTP, MaxCon、MaxSlope和AUC)、形态学参数和TIC类型在良恶性病变间具有显着性差异(P≤0.001)。多变量Logistic回归分析表明K trans、K ep、MaxSlope、病变大小、边界和TIC类型是恶性的独立预测因子。基于qDCE参数的logistic模型、形态学特征结合TIC类型以及所有参数的诊断准确率分别为94.9%、89.0%、95.6%。

本研究表明,qDCE-MRI能够用来提高形态学和动力学分析鉴别乳腺病变良恶性的诊断效能。

原始出处:

Cheng Z, Wu Z, Shi G, et al,Discrimination between benign and malignant breast lesions using volumetric quantitative dynamic contrast-enhanced MR imaging. Eur Radiol. 2017.DOI: 10.1007/s00330-017-5050-2

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=250957, encodeId=3a5a25095e98, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Oct 07 00:37:11 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412013, encodeId=461c1412013b4, content=<a href='/topic/show?id=951b82e63ff' target=_blank style='color:#2F92EE;'>#肿块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82763, encryptionId=951b82e63ff, topicName=肿块)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c58f2824468, createdName=cnxcy, createdTime=Tue Oct 03 02:07:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249427, encodeId=a85824942e71, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Sun Oct 01 14:08:15 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249396, encodeId=f0a124939613, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Sun Oct 01 11:17:39 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249394, encodeId=753c24939475, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Oct 01 11:15:57 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249393, encodeId=da4e2493939f, content= 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Sun Oct 01 11:10:51 CST 2017, time=2017-10-01, status=1, ipAttribution=)]
    2017-10-07 sunfeifeiyang

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=250957, encodeId=3a5a25095e98, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Oct 07 00:37:11 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412013, encodeId=461c1412013b4, content=<a href='/topic/show?id=951b82e63ff' target=_blank style='color:#2F92EE;'>#肿块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82763, encryptionId=951b82e63ff, topicName=肿块)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c58f2824468, createdName=cnxcy, createdTime=Tue Oct 03 02:07:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249427, encodeId=a85824942e71, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Sun Oct 01 14:08:15 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249396, encodeId=f0a124939613, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Sun Oct 01 11:17:39 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249394, encodeId=753c24939475, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Oct 01 11:15:57 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249393, encodeId=da4e2493939f, content= 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Sun Oct 01 11:10:51 CST 2017, time=2017-10-01, status=1, ipAttribution=)]
    2017-10-03 cnxcy
  3. [GetPortalCommentsPageByObjectIdResponse(id=250957, encodeId=3a5a25095e98, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Oct 07 00:37:11 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412013, encodeId=461c1412013b4, content=<a href='/topic/show?id=951b82e63ff' target=_blank style='color:#2F92EE;'>#肿块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82763, encryptionId=951b82e63ff, topicName=肿块)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c58f2824468, createdName=cnxcy, createdTime=Tue Oct 03 02:07:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249427, encodeId=a85824942e71, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Sun Oct 01 14:08:15 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249396, encodeId=f0a124939613, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Sun Oct 01 11:17:39 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249394, encodeId=753c24939475, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Oct 01 11:15:57 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249393, encodeId=da4e2493939f, content= 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Sun Oct 01 11:10:51 CST 2017, time=2017-10-01, status=1, ipAttribution=)]
    2017-10-01 1e17414fm02(暂无匿称)

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=250957, encodeId=3a5a25095e98, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Oct 07 00:37:11 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412013, encodeId=461c1412013b4, content=<a href='/topic/show?id=951b82e63ff' target=_blank style='color:#2F92EE;'>#肿块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82763, encryptionId=951b82e63ff, topicName=肿块)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c58f2824468, createdName=cnxcy, createdTime=Tue Oct 03 02:07:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249427, encodeId=a85824942e71, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Sun Oct 01 14:08:15 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249396, encodeId=f0a124939613, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Sun Oct 01 11:17:39 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249394, encodeId=753c24939475, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Oct 01 11:15:57 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249393, encodeId=da4e2493939f, content= 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Sun Oct 01 11:10:51 CST 2017, time=2017-10-01, status=1, ipAttribution=)]
    2017-10-01 情途末路

    学习了.获益匪浅!感谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=250957, encodeId=3a5a25095e98, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Oct 07 00:37:11 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412013, encodeId=461c1412013b4, content=<a href='/topic/show?id=951b82e63ff' target=_blank style='color:#2F92EE;'>#肿块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82763, encryptionId=951b82e63ff, topicName=肿块)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c58f2824468, createdName=cnxcy, createdTime=Tue Oct 03 02:07:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249427, encodeId=a85824942e71, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Sun Oct 01 14:08:15 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249396, encodeId=f0a124939613, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Sun Oct 01 11:17:39 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249394, encodeId=753c24939475, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Oct 01 11:15:57 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249393, encodeId=da4e2493939f, content= 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Sun Oct 01 11:10:51 CST 2017, time=2017-10-01, status=1, ipAttribution=)]
    2017-10-01 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=250957, encodeId=3a5a25095e98, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Oct 07 00:37:11 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412013, encodeId=461c1412013b4, content=<a href='/topic/show?id=951b82e63ff' target=_blank style='color:#2F92EE;'>#肿块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82763, encryptionId=951b82e63ff, topicName=肿块)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c58f2824468, createdName=cnxcy, createdTime=Tue Oct 03 02:07:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249427, encodeId=a85824942e71, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Sun Oct 01 14:08:15 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249396, encodeId=f0a124939613, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Sun Oct 01 11:17:39 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249394, encodeId=753c24939475, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Oct 01 11:15:57 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249393, encodeId=da4e2493939f, content= 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Sun Oct 01 11:10:51 CST 2017, time=2017-10-01, status=1, ipAttribution=)]
    2017-10-01 衣带渐宽

    学习

    0

相关资讯

避孕药和激素替代疗法究竟会不会引起乳腺癌?

避孕药和激素替代疗法会不会引起乳腺癌?关于这个问题,需要从乳腺癌的病因出发进行分析。我们已经知道,乳腺是受性激素作用的器官,它随体内激素含量的变化而变化。雌激素参与乳腺增值,若长期暴露于雌激素下则会促使乳腺癌的发病。而孕激素对乳腺的作用则褒贬不一,部分学者认为它对乳腺具有保护作用,也有部分人认为它同样参与乳腺增值过程,同样可促进乳腺癌的发病。避孕药与乳腺癌避孕药的成分多为孕雌激素复方制剂,但其中两

2017 CSCO:张清媛教授:年轻乳腺癌患者的生育保护

2017年9月27日~9月29日,第20届全国临床肿瘤大会暨2017年CSCO学术年会在福建厦门隆重召开,在CSCO海峡两岸乳腺癌专场中来自哈尔滨医科大学附属肿瘤医院的张清媛教授发表了《年轻乳腺癌患者的生育保护》的精彩演说一、年轻乳腺癌患者生育需求1.乳腺癌流行病学乳腺癌是女性常见疾病,在欧美他的发病率远高于亚洲,每8位美国女性当中就有1位在一生中有机会被确诊为乳腺癌,随着中国生活方式的西方化,乳

莲和医疗开启CSCO年会下个金色二十年:专场卫星会谱写乳腺癌基因检测治疗新篇章

随着精准医学和个性化医疗的发展,医药行业结构的不断调整,新业务新模式不断涌现,精准医学和行个性化医疗已经从概念走向实践,基因检测技术也在不断走向新的高度,基因研究无疑已经成为“新宠”。在第二十届全国临床肿瘤大会暨2017年CSCO学术年会上,莲和医疗特设乳腺癌专场,以“无创肿瘤基因检测,开启肿瘤精准医疗新纪元”为主题进行了学术讨论,同时,莲和医疗作为国内第一家在香港上市的基因测序公司,一直致力于肿

CSCO 2017:把握驱动,精准治疗—— 江泽飞教授谈HER2阳性乳腺癌治疗现状

年包括曲妥珠单抗在内的靶向药物大幅降价,进入国家医保目录,基层医生对学习靶向药物的使用方法和规范化治疗的需求非常强烈,本次CSCO大会的乳腺癌专场会议的主题是“把握驱动,精准治疗”,对乳腺癌抗HER2治疗进行了深入的解读。【肿瘤资讯】特别采访了CSCO乳腺癌专业委员会江泽飞教授,为我们解读乳腺癌在真实世界的治疗现状和对CSCO乳腺癌指南的推广的想法。

致敬中国研究:阿帕替尼与乳腺癌学界共成长

艾坦(阿帕替尼)是中国自主研制的安全有效的小分子抗血管生成靶向药物,其高度选择性竞争细胞内VEGFR-2的ATP结合位点,阻断下游信号转导,抑制肿瘤组织新血管生成。自阿帕替尼上市以来,逐渐成为肿瘤领域的研究热点,得到全国范围内专家的普遍认可,被应用于多癌种的治疗。2017年9月28日,在CSCO大会现场采访到乳腺癌领域的权威专家,就阿帕替尼在乳腺癌的应用前景进行剖析,且听大咖为您娓娓道来。

乳腺癌新药获美国FDA批准

在国庆长假前夕,美国FDA传来喜讯。今日,FDA宣布批准礼来(Eli Lilly)公司的Verzenio(abemaciclib)上市,与fulvestrant联用治疗HR阳性、HER2阴性的晚期或转移性乳腺癌成人患者。这些患者先前曾接受内分泌疗法,但病情依旧出现进展。FDA也批准Verzenio单独使用,治疗接受过内分泌疗法与化疗,癌症却出现转移的同一患者群体。本款新药的获批上市,将为诸多患者带